Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDX184 + Peg-IFN/RBV in Genotype 1 Chronic Hepatitis C
NCT01011166Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2009
- Primary completion
- Jul 2010
- Modality
- Nucleic Acid-Directed Small Molecules, Metabolically Activated Prodrugs
01
Overview
Phase 2, randomised, double-blind trial of IDX184 in hepatitis C (HCV) (6 arms), sponsored by Merck & Co. Primary endpoints: Change in HCV ribonucleic acid (RNA) level at Day 15, Percentage of participants experiencing adverse events (AEs) up to 28 days and 3 more. Started Nov 2009; status: completed.
02
Drugs
IDX184
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01011166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01011166.